Trial · NCT01439880
Results by group114
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 114
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events | SOC-controlled Period: Standard of Care | All adverse events | 327 | Participants | |
| Number of Participants With Adverse Events | SOC-controlled Period: Evolocumab + SOC | All adverse events | 728 | Participants | |
| Number of Participants With Adverse Events | All-IP Period: SOC / Evolocumab + SOC | All adverse events | 342 | Participants | |
| Number of Participants With Adverse Events | All-IP Period: Evolocumab + SOC / Evolocumab + SOC | All adverse events | 718 | Participants | |
| Number of Participants With Adverse Events | SOC-controlled Period: Standard of Care | Adverse events ≥ grade 3 | 46 | Participants | |
| Number of Participants With Adverse Events | SOC-controlled Period: Evolocumab + SOC | Adverse events ≥ grade 3 | 99 | Participants | |
| Number of Participants With Adverse Events | All-IP Period: SOC / Evolocumab + SOC | Adverse events ≥ grade 3 | 111 | Participants | |
| Number of Participants With Adverse Events | All-IP Period: Evolocumab + SOC / Evolocumab + SOC | Adverse events ≥ grade 3 | 229 | Participants | |
| Number of Participants With Adverse Events | SOC-controlled Period: Standard of Care | Adverse events ≥ grade 4 | 2 | Participants | |
| Number of Participants With Adverse Events | SOC-controlled Period: Evolocumab + SOC | Adverse events ≥ grade 4 | 11 | Participants | |
| Number of Participants With Adverse Events | All-IP Period: SOC / Evolocumab + SOC | Adverse events ≥ grade 4 | 8 | Participants | |
| Number of Participants With Adverse Events | All-IP Period: Evolocumab + SOC / Evolocumab + SOC | Adverse events ≥ grade 4 | 28 | Participants | |
| Number of Participants With Adverse Events | SOC-controlled Period: Standard of Care | Serious adverse events | 30 | Participants | |
| Number of Participants With Adverse Events | SOC-controlled Period: Evolocumab + SOC | Serious adverse events | 72 | Participants | |
| Number of Participants With Adverse Events | All-IP Period: SOC / Evolocumab + SOC | Serious adverse events | 76 | Participants | |
| Number of Participants With Adverse Events | All-IP Period: Evolocumab + SOC / Evolocumab + SOC | Serious adverse events | 172 | Participants | |
| Number of Participants With Adverse Events | SOC-controlled Period: Standard of Care | AEs leading to discontinuation of evolocumab | 0 | Participants | |
| Number of Participants With Adverse Events | SOC-controlled Period: Evolocumab + SOC | AEs leading to discontinuation of evolocumab | 28 | Participants | |
| Number of Participants With Adverse Events | All-IP Period: SOC / Evolocumab + SOC | AEs leading to discontinuation of evolocumab | 16 | Participants | |
| Number of Participants With Adverse Events | All-IP Period: Evolocumab + SOC / Evolocumab + SOC | AEs leading to discontinuation of evolocumab | 27 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01439880/results